Decision Analysis: Omadacycline Relative to Moxifloxacin Among Hospitalized Community-Acquired Bacterial Pneumonia Patients at Risk of Clostridioides difficile Infection

BACKGROUND AND OBJECTIVE: Omadacycline is an aminomethylcycline antibiotic approved in the USA as once-daily intravenous/oral monotherapy for adults with community-acquired bacterial pneumonia (CABP). Omadacycline demonstrated noninferiority to the fluoroquinolone moxifloxacin in a phase III CABP tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Lodise, Thomas P., Mistry, Rohit, Young, Kate, LaPensee, Kenneth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079290/
https://www.ncbi.nlm.nih.gov/pubmed/33604769
http://dx.doi.org/10.1007/s40261-021-01005-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079290/
https://www.ncbi.nlm.nih.gov/pubmed/33604769
http://dx.doi.org/10.1007/s40261-021-01005-w

Ejemplares similares